Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LPO | P22079 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18236753 | 0.81 | OPRK1 (0.43) | OPRK1ADRA2CTRPM5FDPSMEN1 | |
| SCHEMBL1797127 | 0.79 | OPRK1 (0.45) | OPRK1TRPM5FDPSMEN1KMT2A | |
| SCHEMBL46655 | 0.78 | — | — | |
| SCHEMBL5127427 | 0.76 | — | — | |
| SCHEMBL21765308 | 0.76 | — | — | |
| SCHEMBL14274043 | 0.76 | OPRK1 (0.43) | OPRK1TRPM5FDPSMEN1KMT2A | |
| SCHEMBL18065737 | 0.76 | — | — | |
| SCHEMBL19323053 | 0.75 | OPRK1 (0.47) | OPRK1TRPM5FDPSMEN1KMT2A | |
| SCHEMBL13573760 | 0.75 | OPRK1 (0.44) | OPRK1ADRA2CTRPM5FDPSMEN1 | |
| SCHEMBL13573085 | 0.75 | OPRK1 (0.44) | OPRK1ADRA2CTRPM5FDPSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | Aduro Biotech, Inc. (US) | 2021-08-12 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | OPRK1 2433/4885ADRA2C 4438/4885TRPM5 3944/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | OPRK1 3065/4885ADRA2C 4851/4885TRPM5 4083/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | OPRK1 2279/4885ADRA2C 4451/4885TRPM5 1734/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | OPRK1 532/4885ADRA2C 1263/4885TRPM5 2514/4885 |
| US-20210246122-A1 | Triazine Compounds and Uses Thereof | IL5, IL15, TLR5 | OPRK1 3278/4885ADRA2C 2450/4885TRPM5 171/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | OPRK1 15/4885ADRA2C 4/4885TRPM5 821/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | OPRK1 2433/4885ADRA2C 4438/4885TRPM5 3944/4885 |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, RNGTT, HNRNPAB | OPRK1 2800/4885ADRA2C 4840/4885TRPM5 4167/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | OPRK1 3065/4885ADRA2C 4851/4885TRPM5 4083/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | OPRK1 2800/4885ADRA2C 4840/4885TRPM5 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.